203 related articles for article (PubMed ID: 33676851)
1. Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus.
Tan WP; Rastinehad AR; Klotz L; Carroll PR; Emberton M; Feller JF; George AK; Gill IS; Gupta RT; Katz AE; Lebastchi AH; Marks LS; Marra G; Pinto PA; Song DY; Sidana A; Ward JF; Sanchez-Salas R; Rosette J; Polascik TJ;
Urol Oncol; 2021 Nov; 39(11):781.e17-781.e24. PubMed ID: 33676851
[TBL] [Abstract][Full Text] [Related]
2. Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project.
Tay KJ; Scheltema MJ; Ahmed HU; Barret E; Coleman JA; Dominguez-Escrig J; Ghai S; Huang J; Jones JS; Klotz LH; Robertson CN; Sanchez-Salas R; Scionti S; Sivaraman A; de la Rosette J; Polascik TJ
Prostate Cancer Prostatic Dis; 2017 Sep; 20(3):294-299. PubMed ID: 28349978
[TBL] [Abstract][Full Text] [Related]
3. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
Lebastchi AH; George AK; Polascik TJ; Coleman J; de la Rosette J; Turkbey B; Wood BJ; Gorin MA; Sidana A; Ghai S; Tay KJ; Ward JF; Sanchez-Salas R; Muller BG; Malavaud B; Mozer P; Crouzet S; Choyke PL; Ukimura O; Rastinehad AR; Pinto PA
Eur Urol; 2020 Sep; 78(3):371-378. PubMed ID: 32532513
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy.
Fasulo V; Cowan JE; Maggi M; Washington SL; Nguyen HG; Shinohara K; Lazzeri M; Casale P; Carroll PR
Eur Urol Oncol; 2022 Feb; 5(1):61-69. PubMed ID: 33069628
[TBL] [Abstract][Full Text] [Related]
5. Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project.
Muller BG; van den Bos W; Brausi M; Cornud F; Gontero P; Kirkham A; Pinto PA; Polascik TJ; Rastinehad AR; de Reijke TM; de la Rosette JJ; Ukimura O; Villers A; Walz J; Wijkstra H; Marberger M
BJU Int; 2014 Nov; 114(5):698-707. PubMed ID: 24180365
[TBL] [Abstract][Full Text] [Related]
6. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project.
Scheltema MJ; Tay KJ; Postema AW; de Bruin DM; Feller J; Futterer JJ; George AK; Gupta RT; Kahmann F; Kastner C; Laguna MP; Natarajan S; Rais-Bahrami S; Rastinehad AR; de Reijke TM; Salomon G; Stone N; van Velthoven R; Villani R; Villers A; Walz J; Polascik TJ; de la Rosette JJMCH
World J Urol; 2017 May; 35(5):695-701. PubMed ID: 27637908
[TBL] [Abstract][Full Text] [Related]
7. Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Large Multicenter Cohort Study.
von Hardenberg J; Borkowetz A; Siegel F; Kornienko K; Westhoff N; Jordan TB; Hoffmann M; Drerup M; Lieb V; Taymoorian K; Schostak M; Ganzer R; Höfner T; Cash H; Bruendl J;
Eur Urol Focus; 2021 Sep; 7(5):1002-1010. PubMed ID: 33877047
[TBL] [Abstract][Full Text] [Related]
8. Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project.
Muller BG; van den Bos W; Brausi M; Fütterer JJ; Ghai S; Pinto PA; Popeneciu IV; de Reijke TM; Robertson C; de la Rosette JJ; Scionti S; Turkbey B; Wijkstra H; Ukimura O; Polascik TJ
World J Urol; 2015 Oct; 33(10):1503-9. PubMed ID: 25559111
[TBL] [Abstract][Full Text] [Related]
9. Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer.
Jain AL; Sidana A; Maruf M; Sugano D; Calio B; Wood BJ; Pinto PA
Urol Oncol; 2019 Mar; 37(3):182.e1-182.e8. PubMed ID: 30522903
[TBL] [Abstract][Full Text] [Related]
10. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer.
Ahmed HU; Akin O; Coleman JA; Crane S; Emberton M; Goldenberg L; Hricak H; Kattan MW; Kurhanewicz J; Moore CM; Parker C; Polascik TJ; Scardino P; van As N; Villers A;
BJU Int; 2012 Jun; 109(11):1636-47. PubMed ID: 22077593
[TBL] [Abstract][Full Text] [Related]
11. Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.
Postema AW; De Reijke TM; Ukimura O; Van den Bos W; Azzouzi AR; Barret E; Baumunk D; Blana A; Bossi A; Brausi M; Coleman JA; Crouzet S; Dominguez-Escrig J; Eggener S; Ganzer R; Ghai S; Gill IS; Gupta RT; Henkel TO; Hohenfellner M; Jones JS; Kahmann F; Kastner C; Köhrmann KU; Kovacs G; Miano R; van Moorselaar RJ; Mottet N; Osorio L; Pieters BR; Polascik TJ; Rastinehad AR; Salomon G; Sanchez-Salas R; Schostak M; Sentker L; Tay KJ; Varkarakis IM; Villers A; Walz J; De la Rosette JJ
World J Urol; 2016 Oct; 34(10):1373-82. PubMed ID: 26892160
[TBL] [Abstract][Full Text] [Related]
12. The role of magnetic resonance imaging (MRI) in focal therapy for prostate cancer: recommendations from a consensus panel.
Muller BG; Fütterer JJ; Gupta RT; Katz A; Kirkham A; Kurhanewicz J; Moul JW; Pinto PA; Rastinehad AR; Robertson C; de la Rosette J; Sanchez-Salas R; Jones JS; Ukimura O; Verma S; Wijkstra H; Marberger M
BJU Int; 2014 Feb; 113(2):218-27. PubMed ID: 24215670
[TBL] [Abstract][Full Text] [Related]
13. Follow-up after focal therapy in renal masses: an international multidisciplinary Delphi consensus project.
Zondervan PJ; Wagstaff PG; Desai MM; de Bruin DM; Fraga AF; Hadaschik BA; Köllermann J; Liehr UB; Pahernik SA; Schlemmer HP; Wendler JJ; Algaba F; de la Rosette JJ; Laguna Pes MP
World J Urol; 2016 Dec; 34(12):1657-1665. PubMed ID: 27106492
[TBL] [Abstract][Full Text] [Related]
14. Focal laser ablation as clinical treatment of prostate cancer: report from a Delphi consensus project.
van Luijtelaar A; Greenwood BM; Ahmed HU; Barqawi AB; Barret E; Bomers JGR; Brausi MA; Choyke PL; Cooperberg MR; Eggener S; Feller JF; Frauscher F; George AK; Hindley RG; Jenniskens SFM; Klotz L; Kovacs G; Lindner U; Loeb S; Margolis DJ; Marks LS; May S; Mcclure TD; Montironi R; Nour SG; Oto A; Polascik TJ; Rastinehad AR; De Reyke TM; Reijnen JS; de la Rosette JJMCH; Sedelaar JPM; Sperling DS; Walser EM; Ward JF; Villers A; Ghai S; Fütterer JJ
World J Urol; 2019 Oct; 37(10):2147-2153. PubMed ID: 30671638
[TBL] [Abstract][Full Text] [Related]
15. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society.
Marra G; Laguna MP; Walz J; Pavlovich CP; Bianco F; Gregg J; Lebastchi AH; Lepor H; Macek P; Rais-Bahrami S; Robertson C; Rukstalis D; Salomon G; Ukimura O; Abreu AL; Barbe Y; Cathelineau X; Gandaglia G; George AK; Gomez Rivas J; Gupta RT; Lawrentschuk N; Kasivisvanathan V; Lomas D; Malavaud B; Margolis D; Matsuoka Y; Mehralivand S; Moschini M; Oderda M; Orabi H; Rastinehad AR; Remzi M; Schulman A; Shin T; Shiraishi T; Sidana A; Shoji S; Stabile A; Valerio M; Tammisetti VS; Phin Tan W; VAN DEN Bos W; Villers A; Willemse PP; DE LA Rosette J; Polascik T; Sanchez-Salas R;
Minerva Urol Nephrol; 2022 Oct; 74(5):581-589. PubMed ID: 33439577
[TBL] [Abstract][Full Text] [Related]
16. Focal therapy in prostate cancer: international multidisciplinary consensus on trial design.
van den Bos W; Muller BG; Ahmed H; Bangma CH; Barret E; Crouzet S; Eggener SE; Gill IS; Joniau S; Kovacs G; Pahernik S; de la Rosette JJ; Rouvière O; Salomon G; Ward JF; Scardino PT
Eur Urol; 2014 Jun; 65(6):1078-83. PubMed ID: 24444476
[TBL] [Abstract][Full Text] [Related]
17. Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer.
von Hardenberg J; Cash H; Koch D; Borkowetz A; Bruendl J; Leyh-Bannurah SR; Kuru TH; Kowalewski KF; Schindele D; Mala KS; Westhoff N; Blana A; Schostak M;
World J Urol; 2021 Oct; 39(10):3747-3754. PubMed ID: 33881557
[TBL] [Abstract][Full Text] [Related]
18. Salvage Local Treatments After Focal Therapy for Prostate Cancer.
Marra G; Valerio M; Emberton M; Heidenreich A; Crook JM; Bossi A; Pisters LL
Eur Urol Oncol; 2019 Sep; 2(5):526-538. PubMed ID: 31412013
[TBL] [Abstract][Full Text] [Related]
19. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.
Moore CM; Giganti F; Albertsen P; Allen C; Bangma C; Briganti A; Carroll P; Haider M; Kasivisvanathan V; Kirkham A; Klotz L; Ouzzane A; Padhani AR; Panebianco V; Pinto P; Puech P; Rannikko A; Renard-Penna R; Touijer K; Turkbey B; van Poppel H; Valdagni R; Walz J; Schoots I
Eur Urol; 2017 Apr; 71(4):648-655. PubMed ID: 27349615
[TBL] [Abstract][Full Text] [Related]
20. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.
Amin MB; Lin DW; Gore JL; Srigley JR; Samaratunga H; Egevad L; Rubin M; Nacey J; Carter HB; Klotz L; Sandler H; Zietman AL; Holden S; Montironi R; Humphrey PA; Evans AJ; Epstein JI; Delahunt B; McKenney JK; Berney D; Wheeler TM; Chinnaiyan AM; True L; Knudsen B; Hammond ME
Arch Pathol Lab Med; 2014 Oct; 138(10):1387-405. PubMed ID: 25092589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
